Evidence map›Paper›PMID 36084523›Full record

ArticleBiosensors & bioelectronics2022

MINI: A high-throughput point-of-care device for performing hundreds of nucleic acid tests per day.

Duncan McCloskey, Juan Boza, Christopher E Mason, David Erickson

Abstract read
In one paragraph

Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Duncan McCloskeyMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Juan BozaMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Christopher E MasonInstitute for Computational Biomedicine and Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA; The WorldQuant Initiative for Quantitative Prediction, New York, NY, USA.
David EricksonDivision of Nutritional Science, Cornell University, Ithaca, NY, USA; Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY, USA. Electronic address: de54@cornell.edu.

Funding

Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycleR01AI125416 · NIAID · DUKE UNIVERSITY · PI Stacy Michelle Horner · 2016 to 2026
$5.5M
Supplement for MINI point-of-use deviceU01DA053941 · NIDA · UNIVERSITY OF MIAMI CORAL GABLES · PI MASON, CHRISTOPHER EDWARD, SCHURER, STEPHAN C · 2021 to 2022
$5.2M
Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantationR01AI151059 · NIAID · CORNELL UNIVERSITY · PI DADHANIA, DARSHANA, DE VLAMINCK, IWIJN · 2020 to 2024
$3.4M
Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings using KS-DetectUH3CA202723 · NCI · CORNELL UNIVERSITY · PI ERICKSON, DAVID CARL, MARTIN, JEFFREY N · 2018 to 2021
$3.2M
Mapping the RNA modification N6-methyladenosine during Zika virus infectionR21AI129851 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI HORNER, STACY MICHELLE, MASON, CHRISTOPHER EDWARD · 2017 to 2018
$469k
NCI NIH HHS UH3 CA202723NIAID NIH HHS R01 AI125416NIAID NIH HHS R01 AI151059NIAID NIH HHS R21 AI129851NIDA NIH HHS U01 DA053941
6 · The paper itself

Abstract

There are a variety of infectious diseases with a high incidence and mortality in limited resource settings that could benefit from rapid point of care molecular diagnosis. Global health efforts have sought to implement mass-screening programs to provide earlier detection and subsequent treatment in an effort to control transmission and improve health outcomes. However, many of the current diagnostic technologies under development are limited to fewer than 10 samples per run, which inherently restricts the screening throughput of these devices. We have developed a high throughput device called "MINI" that is capable of testing hundreds of samples per day at the point-of-care. MINI can utilize multiple energy sources - electricity, flame, or solar - to perform loop-mediated isothermal amplification (LAMP) in a portable and robust device which is ideal for use in limited resource settings. The unique opto-electronic design of MINI minimizes the energy and space requirements of the device and maximizes the optical isolation and signal clarity, enabling point-of-care analysis of 96 unique samples at once. We show comparable performance to a commercial instrument using two different LAMP assays for Kaposi's sarcoma-associated herpesvirus and a common housekeeping gene, GAPDH. With a single device capable of running hundreds of samples per day, increased access to modern molecular diagnostics could improve health outcomes for a variety of diseases common in limited resource settings.

Indexed as

Biosensing TechniquesCommunicable DiseasesNucleic AcidsHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesOrnithine-Oxo-Acid TransaminasePoint-of-Care SystemsNucleic AcidsOrnithine-Oxo-Acid TransaminaseHigh-throughputLoop-mediated isothermal amplification (LAMP)Molecular diagnosisPoint-of-careScreening

Identifiers

PMID36084523
PMCPMC10960951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.